PMC9184873_01
Kaplan-Meyer survival curves. (A) PFS in all patients, (B) OS in all patients, (C) PFS according to the best response, (D) PFS according to the previous lines of therapy, (E) PFS according to the sex, (F) OS according to the presence of anemia at relapse, G) OS according to the best response.
gr1.jpg
PMC9184873_01_gr1.jpg
fig0001
At a median follow-up of 16 months (range 35 - 1), the median PFS and OS have not been reached (NR); the 12-month PFS and OS rates were 78% and 86,5%, respectively (Fig. 1. In the univariate analysis, the achievement of at least a VGPR, receiving just one line of previous therapy and the male gender resulted in a statistically significant better PFS (Fig. 1. C, D, and E), whereas the absence of anemia at the start of the daratumumab-based triplets and the achievement of at least a VGPR predicted a better OS (Fig. 1.